Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
Noom Inc.
Modality
protein_peptide
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
50Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07588984CT.gov GLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort Study | — | Not Yet Recruiting | — | — | — |
NCT06967389CT.gov Mitigation of Cardiovascular Disease Risks in Children With Extreme Obesity | — | Recruiting | — | — | — |
NCT07096063CT.gov Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk | — | Completed | — | — | — |
NCT05870462CT.gov Semaglutide and Vascular Regeneration | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cardiovascular Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Semaglutide (this asset) | Noom Inc. | Approved | BB · 65 |
| Aspirin | AstraZeneca | P4 | BBB |
| Atorvastatin | Duke University | P4 | BBB |
| Liraglutide | University of Sao Paulo General Hospital | P4 | BBB |
| Rosuvastatin | Nanjing First Hospital, Nanjing Medical University | P4 | BBB |
| Simvastatin | McMaster University | P4 | BBB |
| Ramifentanyl | Helse Fonna | P4 | BBB |
| Degarelix | Rabin Medical Center | P4 | BBB |
| Hydrochlorothiazide | Tehran University of Medical Sciences | P4 | BBB |
+42 more in the Cardiovascular Disorder cohort
Other indications for Semaglutide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metabolic Disease | — | P4 | A · 81 |
| Polycystic Ovary Syndrome | — | P4 | BBB · 79 |
| Type 2 Diabetes Mellitus | — | P4 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Semaglutide in Cardiovascular Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/semaglutide-cardiovascular-disorder-73505
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →